ACM
MRNA icon

Anfield Capital Management’s Moderna MRNA Stock Holding History

Anfield Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-910
Closed -$163K – 85
2022
Q4 		$163K Sell
910
-863
-49% -$141K 0.08% 68
2022
Q3 		$210K Buy
1,773
+63
+4% +$9.56K 0.1% 70
2022
Q2 		$244K Buy
1,710
+252
+17% +$36K 0.11% 68
2022
Q1 		$251K Buy
+1,458
New +$245K 0.09% 75

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Anfield Capital Management's MRNA Position: Q1 2023 in Review

Anfield Capital Management sold out of Moderna (MRNA) in Q1 2023, closing a stake of 910 shares — an estimated $163K sold.

Anfield Capital Management first reported a position in MRNA in Q1 2022 and held it in 4 quarters. The position peaked at $251K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Anfield Capital Management reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Anfield Capital Management sold 910 Moderna shares in Q1 2023, an estimated $163K.
  • Anfield Capital Management first reported a position in Moderna in Q1 2022 and held it in 4 quarters.
  • Anfield Capital Management's Moderna position peaked at $251K in Q1 2022.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.